

The World's **1st Fully-Comprehensive & Non-Invasive Brain Computer Interface (BCI)**—A Revolutionary Clinical Therapeutic & More, *from it's Earliest Pioneers*

Target **Any Brain Region**. Rely on **Millimeter Precision**. Record Activity **Simultaneously**. **Limitless Potential, One System, Zero Surgery, No Joke.**



Opportunity: Strong Early Entry into a Technology Poised to Drastically Change Neurology & Psychiatry, Forever.

Low-Intensity Focused Ultrasound (LIFU) is an [emerging, non-surgical brain stimulation technique](#) with increasingly well-validated [capabilities](#) ushering in a **fundamental change in how we treat the brain**—a massive [leap forward](#) compared with therapies it is primed to replace, including [problematic and ineffective medications](#), as well as [risky, painful, costly surgical implants](#). Since the [1st LIFU clinical trial](#) (led by CEO [Dr. Josh Cain since 2017](#)), hundreds of [scientific studies](#) and [100+ clinical trials](#) collectively demonstrate LIFU's ability to treat brain disorders at their [source](#) without surgery. Symphony is turning LIFU from an experimental technology into a comprehensive, personalized, clinical platform that can treat a vast number of neurological and psychiatric disorders, starting with Parkinson's. We're launching amid an [explosion in neurotech investment](#), including a recent [\\$12M round led by LinkedIn founder Reid Hoffman](#) by another early startup developing LIFU for mental health applications. Born of this ideal timing for market entry and our team's unrivaled direct experience, our practical approach provides the most competitive effort to-date towards an accessible clinical platform to support the increasingly imminent and widespread use of LIFU in clinics and hospitals everywhere. Simultaneously, we are also laying the groundwork for a longer-term vision: an at-home consumer device that allows anyone to interface with their brain, at will—treating disease and much, **much** more.

Leadership & Team

Symphony is led by [Joshua Cain, PhD](#), the **Cognitive Neuroscientist who led the 1st-ever clinical trial using LIFU** alongside [Prof Martin Monti at UCLA](#), placing clinical LIFU on the map by successfully inducing partial recovery in severe Coma patients. With nearly a full decade and 10+ [seminal publications](#) behind him, Cain is among the most experienced in clinical LIFU research and well-prepared to deliver the paradigm-changing tool LIFU will soon become. Cain's Co-founder is [Toby Gollan-Myers](#)—a recent neuroscience graduate and entrepreneur who transitioned from his previous LIFU-based startup and withdrew an offer from Carnegie Mellon's Biomedical Engineering PhD program (fall 2025) to join forces with Cain and build Symphony. Our team and esteemed advisors combine deep technical expertise with clear R&D, regulatory, and commercial strategy. We invite you to join in our mission of setting the clinical and technical standard for this new way to treat some of humanity's most devastating conditions—with widespread adoption.

The Market

Though LIFU can treat many conditions, our initial focus is on **Parkinson's Disease (PD)**: a large, rapidly growing and underserved market (\$5.5B TAM). We offer an appealing alternative to deep-brain stimulation (DBS) implants—a highly effective but invasive and underutilized treatment—the only alternative for over 1/3 with PD who don't respond to medication. Incredibly, LIFU can target the **same brain regions as DBS—without surgery**, performed by a technician (no large clinical team needed). By avoiding the risks, pain, personnel needs, and massive additional costs associated with implants, LIFU **clears major adoption barriers** in this segment (**\$3.3B SAM**). We will initially refine our business model in the Parkinson's space before expanding into other disorders (**\$270B TAM**) and, ultimately, consumer devices.

Product Differentiation and Value Proposition

While research-grade LIFU systems and complex, expensive clinical systems are already under development, we are developing the first fully integrated, user-friendly platform for clinical LIFU. Equipped with the most advanced imaging, targeting, and personalized treatment methods, our platform empowers everyday clinics to deliver precise non-invasive brain stimulation. As the basic ultrasound hardware required for LIFU becomes increasingly commoditized and widely available, our first product is a software/methods package for clinics called **Maestro**®, paired with 3rd-party hardware. Maestro seamlessly integrates the many procedures of today's LIFU into one easy workflow. These include: **1) personalized skull-correction, 2) superior target acquisition, 3) treatment-course planning, 4) adaptive ultrasound beamforming**, and more. Our software-dominant strategy is designed for rapid adoption, data collection, and clinical deployment ahead of our own advanced ultrasound hardware. This hardware will allow for MRI-free, closed-loop, and even-more-precise targeting of any brain region—culminating in a consumer-oriented, at-home brain-computer interface (BCI) for applications like sleep, health, mood, cognition, and, perhaps, even recreation—to name a few. Alongside this, we are advancing an entirely novel **'drug+ultrasound' protocol** to enhance LIFU's effect within specific brain regions, enabling small, lower-energy 24/7 wearable devices. Still its early stages, this is a novel technique that may offer critical advantages for a number of diseases.

Defensible IP:

Our IP portfolio encompasses the critical software, clinical methods, and hardware systems necessary for LIFU's expansion into widespread clinical and at-home use. Provisional filings are underway for AI skull-correction software, novel targeting algorithms, and an optimized method for AI-driven patient-specific treatment protocols. Additional filings cover our drug-plus-ultrasound therapeutic protocols and advanced ultrasound hardware devices. These proprietary technologies and methods enable unique advantages in targeting range, precision, ease-of-use, and eliminating user error in clinical and wearable/take-home form factors.

Funding Requirements & Milestones

We're currently raising a **\$6M round** to fund key R&D and clinical milestones over the next **15-18 months**. These include securing patents, optimizing & validating our treatment software systems, building a full, trial-ready software MVP, and **completing a clinical trial in Parkinson's disease** as well as one in Addiction Disorders. In parallel, we will begin rollout of our software systems to partner clinics and research labs, generating early revenue and building clinical relationships while preparing for a release of the fully-integrated Maestro system in research settings pre-approval, and clinics upon approval. Finally, preparations for hardware R&D (planning, consultants, early recruiting) will precede rapid development of our advanced, closed-loop hardware system (**Aria**®), after a subsequent capital raise.

For Inquiries:

info@symphonyneurotech.com

Considering Investing?


[Let's Meet!](#)




Sincerely, 
Josh Cain, PhD Founding CEO

CONFIDENTIAL : DO NOT DISSEMINATE WITHOUT PERMISSION BY AUTHORIZED SYMPHONY NEUROTECH PERSONNEL

LIFU: Low-Intensity Focused Ultrasound (LIFU) uses the same ultrasound used in imaging to alter brain activity. Today, the most-common form of LIFU uses single element 'transducers'. These act like a magnifying glass, directing a focused cone of ultrasound onto a chosen brain region. This achieves high intensity focal point that modulates activity while sparing areas outside this focus. LIFU has 1st achieved the ability to target deep-brain nuclei involved in neurological and psychiatric diseases *without surgery*. Though too complex to describe here, Symphony will use phased-array systems to do the same, though with, critically, the following additional abilities: **1)** Electronically Steer the Focal Point, **2)** Create a smaller, more-precise focus, **3)** Image brain structure & Function in real-time.



1st LIFU Clinical Trial (UCLA)



The Exponential Adoption of LIFU:

Since 2020, LIFU's ability to alter human brain activity and induce *meaningful therapeutic effects* has become *undeniable*. Since, LIFU use by neuroscientists has *exploded*—immediately followed by *steeply escalating private-sector investment*. Since 2021, **>\$1B** of capital has been deployed to early startups in this space—the majority of which occurring in just the last 2 years, with no sign of this slowing. E.g., the LIFU hardware-1st startup, **Nudge**, recently closed a **\$100M** round. *For perspective, our Founder first trained the co-founders of Nudge in human LIFU using his, then, 7 years of direct experience.* Symphony uniquely benefits from the privileged perspective that **only 10 years** of direct experience in the field can provide.